Health Care International - Repros Therapeutics Inc. Announces That Proellex Significantly Reduces Pain In A U.S. Phase 2 Trial In Women With Moderate To Severe Endometriosis
Repros Therapeutics Inc. (NasdaqGM:RPRX) released positive results from an interim analysis of its U.S. Phase 2 endometriosis trial. The study was designed to assess the effect of Proellex on symptom control in women with endometriosis who have mode
Comments